Abstract:Breast cancer patients are at high risk for bone metastasis. Metastatic bone disease is a major clinical problem that leads to a reduction in mobility, increased risk of pathologic fracture, severe bone pain, and other skeletal-related events. The transcription factor Gli2 drives expression of parathyroid hormone-related protein (PTHrP), which activates osteoclast-mediated bone destruction, and previous studies showed that Gli2 genetic repression in bone-metastatic tumor cells significantly reduces tumor-induced bone destruction. Small molecule inhibitors of Gli2 have been identified; however, the lipophilicity and poor pharmacokinetic profile of these compounds have precluded their success in vivo. In this study, we designed a bone-targeted nanoparticle (BTNP) comprising an amphiphilic diblock copolymer of poly[(propylene sulfide)-block-(alendronate acrylamide-co-N,N-dimethylacrylamide)] [PPS-b-P(Aln-co-DMA)] to encapsulate and preferentially deliver a small molecule Gli2 inhibitor, GANT58, to bone-associated tumors. The mol % of the bisphosphonate Aln in the hydrophilic polymer block was varied in order to optimize BTNP targeting to tumor-associated bone by a combination of nonspecific tumor accumulation (presumably through the enhanced permeation and retention effect) and active bone binding. Although 100% functionalization with Aln created BTNPs with strong bone binding, these BTNPs had highly negative zeta-potential, resulting in shorter circulation time, greater liver uptake, and less distribution to metastatic tumors in bone. However, 10 mol % of Aln in the hydrophilic block generated a formulation with a favorable balance of systemic pharmacokinetics and bone binding, providing the highest bone/liver biodistribution ratio among formulations tested. In an intracardiac tumor cell injection model of breast cancer bone metastasis, treatment with the lead candidate GANT58-BTNP formulation decreased tumor-associated bone lesion area 3-fold and increased bone volume fraction in the tibiae of the mice 2.5-fold. Aln conferred bone targeting to the GANT58-BTNPs, which increased GANT58 concentration in the tumor-associated bone relative to untargeted NPs, and also provided benefit through the direct antiresorptive therapeutic function of Aln. The dual benefit of the Aln in the BTNPs was supported by the observations that drug-free Aln-containing BTNPs improved bone volume fraction in bone-tumor-bearing mice, while GANT58-BTNPs created better therapeutic outcomes than both unloaded BTNPs and GANT58-loaded untargeted NPs. These findings suggest GANT58-BTNPs have potential to potently inhibit tumor-driven osteoclast activation and resultant bone destruction in patients with bone-associated tumor metastases.

A patent review of bisphosphonates in treating bone disease

Emerging anti-cancer molecular mechanisms of aminobisphosphonates

Bisphosphonates for Delivering Drugs to Bone

Bisphosphonates, Specific Inhibitors of Osteoclast Function and a Class of Drugs for Osteoporosis Therapy.

Bisphosphonates Targeting Ion Channels and Musculoskeletal Effects

Repurposing amino-bisphosphonates by liposome formulation for a new role in cancer treatment

Targeting anti-cancer agents to bone using bisphosphonates.

Bisphosphonates and Atypical Femur Fractures: Is the Relationship Causal or Casual?

Calcium-bisphosphonate Nanoparticle Platform as a Prolonged Nanodrug and Bone-Targeted Delivery System for Bone Diseases and Cancers

A multifaceted role of bisphosphonates from palliative care to anti-cancer therapy in solid tumors

Transplantable Delivery Systems Forin Situcontrolled Release of Bisphosphonate in Orthopedic Therapy

Tuning Ligand Density To Optimize Pharmacokinetics of Targeted Nanoparticles for Dual Protection against Tumor-Induced Bone Destruction

Effect of Bisphosphonates on Local Recurrence of Giant Cell Tumor of Bone: a Meta-Analysis.

Bisphosphonates for periprosthetic bone loss after joint arthroplasty: a meta-analysis of 14 randomized controlled trials

Metastatic bone disease: Pathogenesis and therapeutic options: Up-date on bone metastasis management

Metastatic bone disease: Pathogenesis and therapeutic options

Use and safety of bisphosphonates in pediatric osteoporosis

Lipophilic bisphosphonates as dual farnesyl/geranylgeranyl diphosphate synthase inhibitors: an X-ray and NMR investigation.

Concept, diagnosis and classification of bisphosphonate-associated osteonecrosis of the jaws. A review of the literature

[The successful development of bisphosphonates in the therapy of osteoporosis]

Bisphosphonate-loaded bone cement: Background, clinical indications and future perspectives